Drug Information

Drug General Information
Drug ID
D09PJX
Former ID
DAP000756
Drug Name
Tetrabenazine
Synonyms
Nitoman; Rubigen; Tetrabenazina; Tetrabenazinum; Tetrabenzaine; Tetrabenzine; Xenazine; Tetra Benazin; Nitoman (TN); Ro 1-9569; Tetrabenazina [INN-Spanish]; Tetrabenazine (INN); Tetrabenazine [INN:BAN]; Tetrabenazinum [INN-Latin]; Xenazine (TN); Nitoman, Xenazine, Tetrabenazine; Ro 1-9569/12; 1,3,4,6,7,11b-Hexahydro-3-isobutyl-9,10-dimethoxy-2H-benzo(a)quinolizin-2-one; 1,3,4,6,7,11b-Hexahydro-3-isobutyl-9,10-dimethoxy-2H-benzo[a]quinolizin-2-one; 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-Benzo[a]quinolizin-2-one; 2-Oxo-3-isobutyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydro-11bH-benzo[a]quinolizine; 2-Oxo-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11-beta-hexahydro-2H-benzoquinolizine; 2-Oxo-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11.beta.-hexahydro-2H-benzoquinolizine; 2H-Benzo(a)quinolizin-2-one, 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-(9CI); 9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one; 9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one
Drug Type
Small molecular drug
Indication Huntington's disease; Hyperkinetic movement disorder [ICD9: 294.1, 333.4, 333; ICD10:F02.2, G10, G20-G26] Approved [468067], [529941], [530894], [532471], [538577], [551871]
Therapeutic Class
Nephropathic cystinosis therapy
Structure
Download
2D MOL

3D MOL
Formula
C19H27NO3
InChI
InChI=1S/C19H27NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16H,5-7,10-11H2,1-4H3
InChIKey
MKJIEFSOBYUXJB-UHFFFAOYSA-N
CAS Number
CAS 58-46-8
PubChem Compound ID
6018
PubChem Substance ID
13350, 442479, 444004, 5761629, 7914317, 7980763, 8153747, 10528302, 11501999, 14975282, 29216102, 29225032, 46506426, 47331537, 49834869, 49890235, 50086515, 51230337, 56311658, 57323119, 81066398, 85824684, 90341774, 92291104, 96025259, 99358095, 103928969, 104234203, 104253381, 104310884, 106228516, 117913352, 118252979, 121361938, 124530403, 124671347, 124757499, 125164303, 125205323, 125488233, 126658298, 126687256, 128608402, 134222085, 134338041, 135588520, 135610686, 135692279, 137248553, 141463478
SuperDrug ATC ID
N07XX06
SuperDrug CAS ID
cas=000058468
Target and Pathway
Target(s) Synaptic vesicle amine transporter Target Info Blocker [537083], [537569]
KEGG Pathway Synaptic vesicle cycle
Serotonergic synapse
Dopaminergic synapse
Parkinson's disease
Cocaine addiction
Amphetamine addiction
Alcoholism
PANTHER Pathway Adrenaline and noradrenaline biosynthesis
5HT1 type receptor mediated signaling pathway
5HT2 type receptor mediated signaling pathway
5HT3 type receptor mediated signaling pathway
5HT4 type receptor mediated signaling pathway
Dopamine receptor mediated signaling pathway
Nicotine pharmacodynamics pathway
CCKR signaling map ST
Reactome Norepinephrine Neurotransmitter Release Cycle
Na+/Cl- dependent neurotransmitter transporters
WikiPathways Dopaminergic Neurogenesis
Synaptic Vesicle Pathway
Neurotransmitter Release Cycle
Nicotine Activity on Dopaminergic Neurons
References
Ref 468067(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4834).
Ref 5299412008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
Ref 530894Role of tetrabenazine for Huntington's disease-associated chorea. Ann Pharmacother. 2010 Jun;44(6):1080-9.
Ref 532471The druggable genome: Evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication. Annu Rev Pharmacol Toxicol. 2014;54:9-26.
Ref 538577FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 021894.
Ref 551871Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 53708311C-dihydrotetrabenazine PET of the pancreas in subjects with long-standing type 1 diabetes and in healthy controls. J Nucl Med. 2009 Mar;50(3):382-9. Epub 2009 Feb 17.
Ref 537569Dopamine signaling is required for depolarization-induced slow current in cerebellar Purkinje cells. J Neurosci. 2009 Jul 1;29(26):8530-8.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.